Why is pancreatic cancer difficult to treat in the elderly?

Aging Health

Volumn 8, Issue 3, 2012, Pages 301-307

  Raoul, Jean Luc ^a   Turrini, Olivier ^a   Gonçalves, Anthony ^a   Gilabert, Marine ^a   Giovannini, Marc ^a   Rousseau, Frederique ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

elderly; gemcitabine; pancreatic adenocarcinoma; pancreaticoduodenectomy; radiotherapy

Indexed keywords

FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; AGED; AGING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; ELDERLY CARE; ENDOSCOPIC THERAPY; FRAIL ELDERLY; GERIATRIC ASSESSMENT; GERIATRIC DISORDER; HUMAN; MULTIPLE CYCLE TREATMENT; PANCREAS ADENOCARCINOMA; PREOPERATIVE EVALUATION; REVIEW; SURGICAL MORTALITY; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 84862854147     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/ahe.12.20     Document Type: Review

References (45)

1. Hill C, Doyon F. The frequency of cancer in France in year 2002, and trends since 1968. Bull. Cancer 93, 7-11 (2006).
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J. Clin. 60, 277-300 (2010).
3. Berrino F, De Angelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol. 8, 773-783 (2007).
4. Hidalgo M. Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617 (2010).
5. Conroy T, Desseigne F, Ychou M et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364, 1817-1825 (2011).
6. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the monitoring of cancer incidence in Japan project. Jpn J. Clin. Oncol. 39, 850-858 (2009).
7. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N. Engl. J. Med. 364, 2128-2137 (2011).
8. Lahat G, Sever R, Lubezky N et al. Pancreatic cancer: surgery is a feasible therapeutic option for elderly patients. World J. Surg. Oncol. 9, 1-8 (2011).
9. Hatzaras I, Schmidt C, Klemanski D et al. Pancreatic resection in the octogenarian: a safe option for pancreatic malignancy. J. Am. Coll. Surg. 212, 373-377 (2011).
10. Delpero JR, Paye F, Bachelier P. [Pancreatic cancer]. Presented at: [Monographs of the French Surgical Association]. Paris, France, 6-8 October 2010.
11. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 16, 317-323 (1998).
12. Turrini O, Ychou M, Moureau-Zabotto L et al. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: new neoadjuvant regimen was safe and provided an interesting pathologic response. Eur. J. Surg. Oncol. 36, 987-992 (2010).
13. Neoptolemos JP, Stocken DD, Friess H et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N. Engl. J. Med. 350, 1200-1210 (2004).
14. Oettle H, Post S, Neuhaus P et al. Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer. A randomized controlled trial. JAMA 297, 267-277 (2007).
15. Neoptolemos JP, Stocken DD, Bassi C et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection. JAMA 304, 1073-1081 (2010).
16. Maréchal R, Mackey JR, Lai R et al. Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin. Cancer Res. 15, 2913-2919 (2009).
17. Gillen S, Schuster T, Meyer zum Buschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and metanalysis of response and resection percentages. PLoS Med. 7, 1-15 (2010).
18. Barbas AS, Turley RS, Ceppa EP et al. Comparison of outcomes and use of multimodality therapy in young and elderly people undergoing surgical resection of pancreatic cancer. J. Am. Geriat. Soc. 60(2), 344-350 (2012).
19. Inouye S, Bogardus S, Charpentier P et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N. Engl. J. Med. 340, 669-676 (1999).
20. Brouquet A, Cudennec T, Benoist S, Moulias S, Beauchet A, Penna C. Impaired mobility, ASA status and administration of tramadol are risk factors for postoperative delirium in patients aged 75 years or more after major abdominal surgery. Ann. Surg. 251, 759-765 (2010).
21. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 GY, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-2001 FFCD/SFRO study. Ann. Oncol. 19, 1592-1599 (2008).
22. Loehrer PJ Sr, Feng Y et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J. Clin. Oncol. 29, 4105-4112 (2011).
23. Burris AH, Moore MJ, Anderesen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997).
24. Shepherd FA, Abratt RP, Anderson H, Gatzemeier U, Anglin G, Iglesias J. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin. Oncol. 24, 50-55 (1997).
25. Martin C, Ardizzoni A, Rosso R. Gemcitabine. safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging 9, 297-303 (1997).
26. Cunningham D, Chau I, Stocken DD et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 27, 5513-5518 (2009).
27. Herrmann R, Bodoky G, Ruhstaller T et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer : a randomized, multicenter, Phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J. Clin. Oncol. 25, 2212-2217 (2007).
28. Louvet C, Labianca R, Hammel P et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD Phase III trial. J. Clin. Oncol. 23, 3509-3516 (2005).
29. Heinemann V, Quietzsch D, Gieseler F et al. Randomized Phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J. Clin. Oncol. 24, 3946-3952 (2006).
30. Vaccaro V, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 365, 768-769 (2011).
31. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trial Group. J. Clin. Oncol. 25, 1960-1966 (2007).
32. Wong HH, Lemoine NR. Pancreatic cancer: molecular pathogenesis and new therapeutic targets. Nat. Rev. Gastroenterol. Hepatol. 6, 412-422 (2009).
33. Hentic O, Dreyer C, Rebours V et al. Gemcitabine in elderly patients with advanced pancreatic cancer. World J. Gastroenterol. 17, 3497-3502 (2011).
34. Yukisawa S, Ishii H, Matsuyama M, Kuraoka K, Takano K, Kamei A et al. Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older. Jpn J. Clin. Oncol. 41, 76-80 (2011).
35. Aldoss IT, Tashi T, Gonsalves W et al. Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer; a veteran affairs cancer registry analysis. J. Geriat. Oncol. 2, 209-214 (2011).
36. Tempero M, Plunkett W, Ruiz van Haperen V et al. Randomized Phase II comparison of dose-intense gemcitabine: thirty-minute and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. 21, 3402-3408 (2003).
37. Locher C, Fabre-Guillevin E, Brunetti F et al. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit. Rev. Onco. Hematol. 68, 178-182 (2008).
38. Maréchal R, Demols A, Gay F et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimen in elderly patients with advanced pancreatic cancer. Pancreas 36, e16-e21 (2008).
39. Yamagishi Y, Higuchi H, Izumiya M et al. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J. Gastroenterol. 45, 114-115 (2010).
40. Matsumoto K, Miyake Y, Kato H et al. Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. Digestion 84, 230-235 (2011).
41. Van den Bosch RP, van der Schelling GP, Klinkenbijl JHG, Mulder PGH, van Blankenstein M, Jeekel J. Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas. Ann. Surg. 219, 18-24 (1994).
42. Giovannini M, Moutardier V, Pesenti C et al. Endoscopic ultrasound-guided bilioduodenal anastomosis: a new technique for biliary drainage. Endoscopy 33, 898-900 (2001).
43. Maetani I, Ukita T, Tada T et al. Metallic stents for gastric outlet obstruction: reintervention rate is lower with uncovered versus covered stents, despite similar outcomes. Gastrointest. Endosc. 69, 806-812 (2009).
44. Puli SR, Reddy JB, Bechtold ML, Antillon MR, Brugge WR. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. Dig. Dis. Sci. 54, 2330-2337 (2009).
45. Majumder S, Chubineh S, Birk J. Pancreatic cancer: an endoscopic perspective. Expert Rev. Gastroenterol. Hepatol. 6, 95-104 (2012).